-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News on March 22nd.
Gynecological infectious diseases mainly refer to infectious inflammation of the reproductive system caused by pathogens invading the female genitourinary system.
It is a common type of disease in gynecology, mainly including vulvovaginitis (trichomoniasis, vulvovaginitis) candidiasis, bacterial vaginosis), cervicitis, pelvic inflammatory disease, genital tuberculosis, and so on
.
Cervicitis is a common gynecological disease, accounting for about 40% to 50% of the total number of gynecological outpatient clinics.
It mostly occurs in women of childbearing age and has two types, acute and chronic
.
The drug treatment of gynecological infectious diseases is divided into systemic drugs and topical drugs.
The drugs specially used for the treatment of gynecological infectious diseases are mainly used for topical drugs in the reproductive tract
.
Data from sample hospitals in PDB key cities show that gynecological anti-infective agents account for about 0.
2% of the market share in the hospital market, and the market scale is small
.
In recent years, the gynecological anti-infective preparation market has shown a slight upward trend, with an increase of 10% over the previous year in 2019, reaching 560 million yuan (Figure 1)
.
Affected by the new crown pneumonia epidemic in 2020, hospital market sales have declined significantly, and annual sales have dropped by about 17% compared with the previous year.
However, as the epidemic is under control, patients' medical treatment gradually returns to normal, and it is expected that the demand for treatment will gradually increase in 2021.
Release, the market will also pick up
.
Figure 1 Changes in the market scale of gynecological anti-infective preparations in PDB sample hospitals From the perspective of generic name varieties, there are currently about 33 generic-named varieties in the hospital market.
The top 10 varieties together account for about 92% of the gynecological anti-infective preparation market.
The two varieties of recombinant human interferon α2b and nifuratel nystatin compound accounted for nearly half of the market share.
The market share of recombinant human interferon α2b increased significantly, while the market share of nifuratel nystatin compound It shows a downward trend (Figure 2)
.
These 10 species are listed more than 15 years old varieties, but the overall competitive enterprisesThere are not many.
Except for 3 varieties with more than 20 competitors, the other 7 varieties have no more than 10 competitors.
Among them, Lactobacillus capsules for vaginal use (Inner Mongolia Shuangqi Pharmaceutical Co.
, Ltd.
) and Lactic acid bacteria vaginal capsules (Xi'an Zhenghao Biopharmaceutical Co.
, Ltd.
) currently only has one manufacturer (Table 1)
.
Judging from the active ingredients of the drugs involved in these 10 varieties, in fact only recombinant human interferon α2b, nifuratel, clotrimazole, metronidazole, live Lactobacillus bacteria, clindamycin, nystatin, chlorine There are 8 ingredients such as hexamine
.
This point does not match the requirements of frequent recurrence of gynecological infectious diseases and involving multiple pathogens
.
Obviously, in the field of gynecological anti-infective preparations, no new varieties with obvious advantages have been seen for a long time
.
Figure 2 PDB sample hospital gynecological anti-infective agents TOP10 market share of varieties of Table 1 PDB sample gynecological hospital anti-infective market preparation breeds TOP10 number of competitors recombinant human interferon α2b and lactobacillus vaginal preparations gynecological anti-infective agents on the market Relatively "new" variety, and the mechanism of action is different from drugs that act on pathogens such as nifuratel, nystatin, clotrimazole, metronidazole, clindamycin, etc.
, and act in a way of regulating immunity or flora Therapeutic effect
.
1.
Recombinant human interferon α2b
Recombinant human interferon α2b has broad-spectrum antiviral, anti-tumor, inhibiting cell proliferation, and improving immune function.
It binds to cell surface receptors to induce cells to produce a variety of antiviral proteins and inhibit virus in cells.
Propagation within and improving immune function include enhancing the phagocytic function of macrophages, enhancing the cytotoxicity of lymphocytes to target cells and the function of natural killer cells
.
Recombinant human interferon α2b vaginal preparations are mainly used to treat chronic cervicitis, cervical erosion, vaginitis, etc.
caused by vaginal virus infection
.
Data from sample hospitals in PDB key cities show that in recent years, the market for recombinant human interferon α2b vaginal preparations has shown a year-on-year growth.
Except for the decline in the market due to the impact of the new crown epidemic in 2020, the market size will increase by about 10% every year.
Rising (Figure 3), the sales scale in 2019 is 140 million yuan, and the scale in 2020 is 120 million yuan
.
Figure 3 The market size of recombinant human interferon α2b vaginal preparations in PDB sample hospitals.
The products of recombinant human interferon α2b vaginal preparations include: vaginal effervescent capsules (Xinfuning from Shanghai Huaxin Biotech Co.
, Ltd.
), vaginal effervescent tablets (Beijing Kaiyin) Jin Shuxi from Science and Technology Co.
, Ltd.
) and vaginal suppositories (Shuang Yinjie from Changchun Biological Products Research Institute Co.
, Ltd.
; Andafen from Anhui Anke Biological Engineering (Group) Co.
, Ltd.
)
.
The four companies have different product formulations, specifications, and price differences.
Shuangyinjie from Changchun Institute of Biological Products currently has the highest price, followed by Jinshuxi from Beijing Kaiin Technology.
The specifications of these two varieties are both 500,000 IU.
The former is a suppository, the latter is a vaginal effervescent tablet.
The vaginal effervescent capsule of Shanghai Huaxin Biologics has the highest unit preparation content, but the price is lower (Table 2)
.
In terms of sales scale and market share, Shanghai Huaxin Biotechnology currently accounts for nearly half of the recombinant human interferon α2b vaginal preparation market, but the market has declined in recent years.
Sales in PDB sample hospitals have increased from 105 million yuan in 2018 , Dropped to 58 million yuan in 2020, and its market share dropped from over 90% to 47%
.
On the contrary, Beijing Kaiin Technology's sales in this product market have grown rapidly in recent years.
Sales in PDB sample hospitals have increased from 23 million yuan in 2018 to 56 million yuan in 2020, with a market share of less than 5%.
Increased to more than 44%, Jin Shuxi formed a strong competition with Xin Funing
.
Based on the average winning bid price, the cost of Jin Shuxi for a course of treatment (9 days) is about 403 yuan, and the cost of Xinfuning for a course of treatment is about 174 yuan.
It can be seen that the treatment cost of Jinshuxi for a course of treatment is more than twice that of Xinfuning.
.
Due to the high price, the sales growth can obviously be reflected in the rapid growth of Jinshuxi's sales, and the higher treatment costs can still compete quickly to obtain the market of similar varieties, which to some extent shows that the current price sensitivity of this product field is relatively low.
, And it is more sensitive to the characteristics of dosage forms and treatments, reflecting the high demand for new varieties in the market
.
Table 2 The price of recombinant human interferon α2b vaginal preparations Figure 4 The sales scale of manufacturers of recombinant human interferon α2b vaginal preparations in PDB sample hospitals (million yuan) Figure 5 The market of manufacturers of recombinant human interferon α2b vaginal preparations in PDB sample hospitals Portion
2.
Viable Lactobacillus
Vaginal Lactobacillus capsules can directly supplement the normal physiological bacteria in the vagina, adjust the balance of the vaginal flora, inhibit and eliminate harmful bacteria in the vagina, and are suitable for bacteria caused by the disorder of the flora.
Treatment of sexual vaginosis
.
Lactobacillus live bacteria are sensitive to a variety of antibiotics such as β-lactams, macrolides, aminoglycosides, etc.
, and need to be staggered with these types of drugs when used.
Therefore, whether the prescription and use are reasonable, it may be affected by this product.
Has an impact on the efficacy
.
Lactobacillus viable capsules for vagina are currently only produced by Inner Mongolia Shuangqi Pharmaceutical Co.
, Ltd.
, and the product name is "Dingjunsheng"
.
According to the market data of sample hospitals in PDB's key cities, except for 2020, the annual sales of "Dingjunsheng" has increased rapidly, with an average annual growth rate of about 13%.
In 2019, it reached 33 million yuan.
Although the sales in 2020 will be affected by the new crown The impact of the epidemic has declined, but the market share of gynecological anti-infective preparations is still on the rise, and the market share has increased to 6.
1%
.
At present, the domestic market for vaginal lactobacillus live bacteria capsules is the only lactic acid bacteria vaginal capsule (made from live enterococcus), but the market for lactic acid bacteria vaginal capsules is small, only less than one-third of the former
.
At present, the sales of lactic acid bacteria vaginal capsules in PDB sample hospitals are 9.
8 million yuan, and the market has also shown a rapid upward trend in the past three years, with an average annual growth rate of more than 10%
.
Although the two varieties of viable lactobacillus capsules and lactic acid bacteria vaginal capsules for vagina are not particularly new, they have seen significant market growth in recent years.
It can be seen that adjusting the balance of vaginal microenvironment is a treatment method to treat gynecological infections.
Diseases are being adopted more and more, showing the growth of market demand
.
Figure 6: Sales and market share of live vaginal lactobacillus capsules in PDB sample hospitals.
Gynecological infectious diseases are common and frequently-occurring diseases in gynecology.
They are the source of many serious gynecological diseases.
While harming women’s health , they also seriously affect women’s lives.
Quality
.
In the field of gynecological anti-infective preparations, old drugs are still the majority.
Recombinant human interferon α2b vaginal preparations, vaginal lactobacillus viable bacteria and lactic acid bacteria preparations have been relatively active in recent years, and directly targeted No new varieties of pathogen drugs have entered this market segment
.
Therefore, in response to the characteristics of frequent recurrence of gynecological infectious diseases and multiple types of infections, this field urgently needs to introduce more good drugs and new drugs to improve efficacy, reduce adverse reactions , and improve the quality of life of patients
.
All data in this article comes from the PDB Drug Comprehensive Database (pdb.
pharmadl.
com)
.
Gynecological infectious diseases mainly refer to infectious inflammation of the reproductive system caused by pathogens invading the female genitourinary system.
It is a common type of disease in gynecology, mainly including vulvovaginitis (trichomoniasis, vulvovaginitis) candidiasis, bacterial vaginosis), cervicitis, pelvic inflammatory disease, genital tuberculosis, and so on
.
Cervicitis is a common gynecological disease, accounting for about 40% to 50% of the total number of gynecological outpatient clinics.
It mostly occurs in women of childbearing age and has two types, acute and chronic
.
The drug treatment of gynecological infectious diseases is divided into systemic drugs and topical drugs.
The drugs specially used for the treatment of gynecological infectious diseases are mainly used for topical drugs in the reproductive tract
.
Data from sample hospitals in PDB key cities show that gynecological anti-infective agents account for about 0.
2% of the market share in the hospital market, and the market scale is small
.
In recent years, the gynecological anti-infective preparation market has shown a slight upward trend, with an increase of 10% over the previous year in 2019, reaching 560 million yuan (Figure 1)
.
Affected by the new crown pneumonia epidemic in 2020, hospital market sales have declined significantly, and annual sales have dropped by about 17% compared with the previous year.
However, as the epidemic is under control, patients' medical treatment gradually returns to normal, and it is expected that the demand for treatment will gradually increase in 2021.
Release, the market will also pick up
.
Figure 1 Changes in the market scale of gynecological anti-infective preparations in PDB sample hospitals From the perspective of generic name varieties, there are currently about 33 generic-named varieties in the hospital market.
The top 10 varieties together account for about 92% of the gynecological anti-infective preparation market.
The two varieties of recombinant human interferon α2b and nifuratel nystatin compound accounted for nearly half of the market share.
The market share of recombinant human interferon α2b increased significantly, while the market share of nifuratel nystatin compound It shows a downward trend (Figure 2)
.
These 10 species are listed more than 15 years old varieties, but the overall competitive enterprisesThere are not many.
Except for 3 varieties with more than 20 competitors, the other 7 varieties have no more than 10 competitors.
Among them, Lactobacillus capsules for vaginal use (Inner Mongolia Shuangqi Pharmaceutical Co.
, Ltd.
) and Lactic acid bacteria vaginal capsules (Xi'an Zhenghao Biopharmaceutical Co.
, Ltd.
) currently only has one manufacturer (Table 1)
.
Judging from the active ingredients of the drugs involved in these 10 varieties, in fact only recombinant human interferon α2b, nifuratel, clotrimazole, metronidazole, live Lactobacillus bacteria, clindamycin, nystatin, chlorine There are 8 ingredients such as hexamine
.
This point does not match the requirements of frequent recurrence of gynecological infectious diseases and involving multiple pathogens
.
Obviously, in the field of gynecological anti-infective preparations, no new varieties with obvious advantages have been seen for a long time
.
Figure 2 PDB sample hospital gynecological anti-infective agents TOP10 market share of varieties of Table 1 PDB sample gynecological hospital anti-infective market preparation breeds TOP10 number of competitors recombinant human interferon α2b and lactobacillus vaginal preparations gynecological anti-infective agents on the market Relatively "new" variety, and the mechanism of action is different from drugs that act on pathogens such as nifuratel, nystatin, clotrimazole, metronidazole, clindamycin, etc.
, and act in a way of regulating immunity or flora Therapeutic effect
.
1.
Recombinant human interferon α2b
Recombinant human interferon α2b has broad-spectrum antiviral, anti-tumor, inhibiting cell proliferation, and improving immune function.
It binds to cell surface receptors to induce cells to produce a variety of antiviral proteins and inhibit virus in cells.
Propagation within and improving immune function include enhancing the phagocytic function of macrophages, enhancing the cytotoxicity of lymphocytes to target cells and the function of natural killer cells
.
Recombinant human interferon α2b vaginal preparations are mainly used to treat chronic cervicitis, cervical erosion, vaginitis, etc.
caused by vaginal virus infection
.
Data from sample hospitals in PDB key cities show that in recent years, the market for recombinant human interferon α2b vaginal preparations has shown a year-on-year growth.
Except for the decline in the market due to the impact of the new crown epidemic in 2020, the market size will increase by about 10% every year.
Rising (Figure 3), the sales scale in 2019 is 140 million yuan, and the scale in 2020 is 120 million yuan
.
Figure 3 The market size of recombinant human interferon α2b vaginal preparations in PDB sample hospitals.
The products of recombinant human interferon α2b vaginal preparations include: vaginal effervescent capsules (Xinfuning from Shanghai Huaxin Biotech Co.
, Ltd.
), vaginal effervescent tablets (Beijing Kaiyin) Jin Shuxi from Science and Technology Co.
, Ltd.
) and vaginal suppositories (Shuang Yinjie from Changchun Biological Products Research Institute Co.
, Ltd.
; Andafen from Anhui Anke Biological Engineering (Group) Co.
, Ltd.
)
.
The four companies have different product formulations, specifications, and price differences.
Shuangyinjie from Changchun Institute of Biological Products currently has the highest price, followed by Jinshuxi from Beijing Kaiin Technology.
The specifications of these two varieties are both 500,000 IU.
The former is a suppository, the latter is a vaginal effervescent tablet.
The vaginal effervescent capsule of Shanghai Huaxin Biologics has the highest unit preparation content, but the price is lower (Table 2)
.
In terms of sales scale and market share, Shanghai Huaxin Biotechnology currently accounts for nearly half of the recombinant human interferon α2b vaginal preparation market, but the market has declined in recent years.
Sales in PDB sample hospitals have increased from 105 million yuan in 2018 , Dropped to 58 million yuan in 2020, and its market share dropped from over 90% to 47%
.
On the contrary, Beijing Kaiin Technology's sales in this product market have grown rapidly in recent years.
Sales in PDB sample hospitals have increased from 23 million yuan in 2018 to 56 million yuan in 2020, with a market share of less than 5%.
Increased to more than 44%, Jin Shuxi formed a strong competition with Xin Funing
.
Based on the average winning bid price, the cost of Jin Shuxi for a course of treatment (9 days) is about 403 yuan, and the cost of Xinfuning for a course of treatment is about 174 yuan.
It can be seen that the treatment cost of Jinshuxi for a course of treatment is more than twice that of Xinfuning.
.
Due to the high price, the sales growth can obviously be reflected in the rapid growth of Jinshuxi's sales, and the higher treatment costs can still compete quickly to obtain the market of similar varieties, which to some extent shows that the current price sensitivity of this product field is relatively low.
, And it is more sensitive to the characteristics of dosage forms and treatments, reflecting the high demand for new varieties in the market
.
Table 2 The price of recombinant human interferon α2b vaginal preparations Figure 4 The sales scale of manufacturers of recombinant human interferon α2b vaginal preparations in PDB sample hospitals (million yuan) Figure 5 The market of manufacturers of recombinant human interferon α2b vaginal preparations in PDB sample hospitals Portion
2.
Viable Lactobacillus
Vaginal Lactobacillus capsules can directly supplement the normal physiological bacteria in the vagina, adjust the balance of the vaginal flora, inhibit and eliminate harmful bacteria in the vagina, and are suitable for bacteria caused by the disorder of the flora.
Treatment of sexual vaginosis
.
Lactobacillus live bacteria are sensitive to a variety of antibiotics such as β-lactams, macrolides, aminoglycosides, etc.
, and need to be staggered with these types of drugs when used.
Therefore, whether the prescription and use are reasonable, it may be affected by this product.
Has an impact on the efficacy
.
Lactobacillus viable capsules for vagina are currently only produced by Inner Mongolia Shuangqi Pharmaceutical Co.
, Ltd.
, and the product name is "Dingjunsheng"
.
According to the market data of sample hospitals in PDB's key cities, except for 2020, the annual sales of "Dingjunsheng" has increased rapidly, with an average annual growth rate of about 13%.
In 2019, it reached 33 million yuan.
Although the sales in 2020 will be affected by the new crown The impact of the epidemic has declined, but the market share of gynecological anti-infective preparations is still on the rise, and the market share has increased to 6.
1%
.
At present, the domestic market for vaginal lactobacillus live bacteria capsules is the only lactic acid bacteria vaginal capsule (made from live enterococcus), but the market for lactic acid bacteria vaginal capsules is small, only less than one-third of the former
.
At present, the sales of lactic acid bacteria vaginal capsules in PDB sample hospitals are 9.
8 million yuan, and the market has also shown a rapid upward trend in the past three years, with an average annual growth rate of more than 10%
.
Although the two varieties of viable lactobacillus capsules and lactic acid bacteria vaginal capsules for vagina are not particularly new, they have seen significant market growth in recent years.
It can be seen that adjusting the balance of vaginal microenvironment is a treatment method to treat gynecological infections.
Diseases are being adopted more and more, showing the growth of market demand
.
Figure 6: Sales and market share of live vaginal lactobacillus capsules in PDB sample hospitals.
Gynecological infectious diseases are common and frequently-occurring diseases in gynecology.
They are the source of many serious gynecological diseases.
While harming women’s health , they also seriously affect women’s lives.
Quality
.
In the field of gynecological anti-infective preparations, old drugs are still the majority.
Recombinant human interferon α2b vaginal preparations, vaginal lactobacillus viable bacteria and lactic acid bacteria preparations have been relatively active in recent years, and directly targeted No new varieties of pathogen drugs have entered this market segment
.
Therefore, in response to the characteristics of frequent recurrence of gynecological infectious diseases and multiple types of infections, this field urgently needs to introduce more good drugs and new drugs to improve efficacy, reduce adverse reactions , and improve the quality of life of patients
.
All data in this article comes from the PDB Drug Comprehensive Database (pdb.
pharmadl.
com)
.
